Vaccinex

Vaccinex Financial Leverage

The Financial Leverage (Equity Multiplier) of Vaccinex (VCNX) as of Nov 22, 2026 is -0.24. In the previous year, Financial Leverage (Equity Multiplier) was -1.04 — a change of -77.29% (higher).

Financial Leverage

-0.24

YoY

-77.29%

Last updated:

Financial Leverage (Equity Multiplier) of Vaccinex is 2025 -0.24 . Financial Leverage (Equity Multiplier) of Vaccinex was 2024 -1.04 . It decreases by -77.29% higher compared to the previous year.

The Vaccinex Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-2.56 USD
Jan 1, 2019
-0.18 USD
Jan 1, 2020
-0.44 USD
Jan 1, 2021
1.33 USD
Jan 1, 2022
1.54 USD
Jan 1, 2023
-1.57 USD
Jan 1, 2024
-1.04 USD
Jan 1, 2025
-0.24 USD
The Vaccinex Financial Leverage history
YEARFinancial LeverageYoY
-0.24-77.29%
-1.04-33.59%
-1.57-202.28%
1.54+15.67%
1.33-401.58%
-0.44+150.94%
-0.18-93.13%
-2.56-18.78%
-3.15+268.53%
-0.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vaccinex Stock analysis

What does Vaccinex do? Vaccinex, Inc. develops targeted biotherapeutics for serious diseases such as cancer, neurodegenerative diseases, and autoimmune disorders. The company generates revenue through its SEMA4D antibody platform, focusing on VX15 for non-small cell lung cancer, osteosarcoma, melanoma, and Huntington’s disease. It also utilizes the ActiveMAb antibody discovery platform for developing VX5, which is in preclinical stages for multiple sclerosis and other autoimmune disorders. Vaccinex targets healthcare providers and pharmaceutical companies seeking novel treatments for unmet medical needs. Vaccinex's lead product candidate VX15 is developed using the SEMA4D platform to address non-small cell lung cancer, osteosarcoma, and melanoma. The company's ActiveMAb platform supports the creation of high-affinity human monoclonal antibodies, which are used in VX5 for multiple sclerosis treatment. These platforms enable Vaccinex to offer innovative solutions for diseases with limited therapeutic options. The company's focus on clinical-stage development means it currently does not generate revenue from product sales but relies on partnerships and potential future licensing agreements. Vaccinex's target segments include patients with non-small cell lung cancer, osteosarcoma, melanoma, Huntington’s disease, and multiple sclerosis, as well as pharmaceutical companies interested in acquiring or co-developing its platforms and product candidates. Vaccinex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaccinex stock

Financial Leverage (Equity Multiplier) of Vaccinex is -0.24 in 2025.

Financial Leverage (Equity Multiplier) of Vaccinex changed from -1.04 to -0.24, representing a -77.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Vaccinex since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Vaccinex with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Vaccinex

All Key Metrics — Vaccinex